Payment overview · 2025
General Payments
$114.20
6 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Cirino, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, OH · NPI 1194766204
Verified facts
What the public records show
CMS Open Payments records show Robert Cirino, MD received $114.20 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.71 | 36.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.41 | 36.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.08 | 15.8% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $13.00 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $114.20 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $13.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 235 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
235 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1560 | 463 |
| Amlodipine Besylate | Amlodipine Besylate | 1285 | 345 |
| Levothyroxine Sodium | Levothyroxine Sodium | 999 | 255 |
| Lisinopril | Lisinopril | 722 | 199 |
| Losartan Potassium | Losartan Potassium | 635 | 176 |
| Metoprolol Succinate | Metoprolol Succinate | 610 | 167 |
| Hydrochlorothiazide | Hydrochlorothiazide | 589 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 537 | 158 |
| Tamsulosin Hcl | Tamsulosin Hcl | 462 | 136 |
| Simvastatin | Simvastatin | 428 | 118 |
| Omeprazole | Omeprazole | 410 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 353 | 100 |
| Metformin Hcl | Metformin Hcl | 319 | 97 |
| Trazodone Hcl | Trazodone Hcl | 288 | 81 |
| Allopurinol | Allopurinol | 266 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 83 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 254 | 72 |
| Glimepiride | Glimepiride | 242 | 68 |
| Furosemide | Furosemide | 241 | 79 |
| Sertraline Hcl | Sertraline Hcl | 239 | 62 |
| Eliquis | Apixaban | 235 | 60 |
| Synthroid | Levothyroxine Sodium | 196 | 59 |
| Montelukast Sodium | Montelukast Sodium | 191 | 70 |
| Gabapentin | Gabapentin | 185 | 49 |
| Meloxicam | Meloxicam | 166 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 35 |
| Prednisone | Prednisone | 146 | 76 |
| Finasteride | Finasteride | 143 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 29 |
| Potassium Chloride | Potassium Chloride | 134 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 59 |
| Atenolol | Atenolol | 109 | 32 |
| Alendronate Sodium | Alendronate Sodium | 108 | 25 |
| Carvedilol | Carvedilol | 108 | 37 |
| Azithromycin | Azithromycin | 104 | 104 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 31 |
| Mirtazapine | Mirtazapine | 101 | 24 |
| Metformin Hcl Er | Metformin Hcl | 95 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 28 |
| Mounjaro | Tirzepatide | 94 | 15 |
| Jardiance | Empagliflozin | 93 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 80 |
| Alprazolam | Alprazolam | 90 | 21 |
| Spironolactone | Spironolactone | 90 | 27 |
| Amoxicillin | Amoxicillin | 87 | 78 |
| Doxazosin Mesylate | Doxazosin Mesylate | 81 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Paxlovid | Nirmatrelvir/Ritonavir | 79 | 79 |
| Buspirone Hcl | Buspirone Hcl | 78 | 24 |
| Ezetimibe | Ezetimibe | 76 | 24 |
| Lovastatin | Lovastatin | 75 | 18 |
| Famotidine | Famotidine | 70 | 22 |
| Methylprednisolone | Methylprednisolone | 69 | 63 |
| Ramipril | Ramipril | 68 | 16 |
| Propranolol Hcl | Propranolol Hcl | 63 | 17 |
| Lansoprazole | Lansoprazole | 61 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 25 |
| Farxiga | Dapagliflozin Propanediol | 58 | 15 |
| Xarelto | Rivaroxaban | 57 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Lorazepam | Lorazepam | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 13 |
| Bupropion Xl | Bupropion Hcl | 55 | 19 |
| Celecoxib | Celecoxib | 51 | 11 |
| Januvia | Sitagliptin Phosphate | 51 | 13 |
| Memantine Hcl | Memantine Hcl | 51 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 44 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 31 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Colchicine | Colchicine | 42 | 21 |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Cephalexin | Cephalexin | 40 | 36 |
| Acyclovir | Acyclovir | 38 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Chlorthalidone | Chlorthalidone | 35 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Hydrocortisone | Hydrocortisone | 25 | 15 |
| Indapamide | Indapamide | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 22 |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 17 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Desonide | Desonide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Ketoprofen | Ketoprofen | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Zoloft | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $114.20 · 6 records | Amgen Inc. | AREXVY, ELIQUIS, EVENITY, Fibroscan, PROLIA, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error